Literature DB >> 32387392

Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections.

Alireza Neshani1, Hamid Sedighian2, Seyed Ali Mirhosseini2, Kiarash Ghazvini3, Hosna Zare4, Abolfazl Jahangiri5.   

Abstract

BACKGROUND: With the increasing rate of antibiotic resistance in Acinetobacter, the World Health Organization introduced the carbapenem-resistant isolates in the priority pathogens list for which innovative new treatments are urgently needed. Antimicrobial peptides (AMPs) are one of the antimicrobial agents with high potential to produce new anti-Acinetobacter drugs. This review aims to summarize recent advances and compare AMPs with anti-Acinetobacter baumannii activity.
METHODS: Active AMPs against Acinetobacter were considered, and essential features, including structure, mechanism of action, anti-A. baumannii potent, and other prominent characteristics, were investigated and compared to each other. In this regard, the Google Scholar search engine and databases of PubMed, Scopus, and Web of Science were used.
RESULTS: Forty-six anti-Acinetobacter peptides were identified and classified into ten groups: Cathelicidins, Defensins, Frog AMPs, Melittin, Cecropins, Mastoparan, Histatins, Dermcidins, Tachyplesins, and computationally designed AMPs. According to the Minimum Inhibitory Concentration (MIC) reports, six peptides of Melittin, Histatin-8, Omega76, AM-CATH36, Hymenochirin, and Mastoparan have the highest anti-A. baumannii power against sensitive and antibiotic-resistant isolates. All anti-Acinetobacter peptides except Dermcidin have a net positive charge. Most of these peptides have alpha-helical structure; however, β-sheet and other structures have been observed among them. The mechanism of action of these antimicrobial agents is divided into two categories of membrane-based and intracellular target-based attack.
CONCLUSION: Evidence from this review indicates that AMPs would be likely among the main anti-A. baumannii drugs in the post-antibiotic era. Also, the application of computer science to increase anti-A. baumannii activity and reduce toxicity could be helpful.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AMPs; Acinetobacter baumannii; Antimicrobial peptide; Drug resistance

Mesh:

Substances:

Year:  2020        PMID: 32387392     DOI: 10.1016/j.micpath.2020.104238

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  6 in total

1.  A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Authors:  Mohammad Reza Rahbar; Shaden M H Mubarak; Anahita Hessami; Bahman Khalesi; Navid Pourzardosht; Saeed Khalili; Kobra Ahmadi Zanoos; Abolfazl Jahangiri
Journal:  Sci Rep       Date:  2022-06-27       Impact factor: 4.996

Review 2.  Evasion of Antimicrobial Activity in Acinetobacter baumannii by Target Site Modifications: An Effective Resistance Mechanism.

Authors:  Arturo Martínez-Trejo; Juan Manuel Ruiz-Ruiz; Luis Uriel Gonzalez-Avila; Andrés Saldaña-Padilla; Cecilia Hernández-Cortez; Miguel Angel Loyola-Cruz; Juan Manuel Bello-López; Graciela Castro-Escarpulli
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

3.  Therapeutic Potential of Novel Mastoparan-Chitosan Nanoconstructs Against Clinical MDR Acinetobacter baumannii: In silico, in vitro and in vivo Studies.

Authors:  Afreenish Hassan; Aamer Ikram; Abida Raza; Sidra Saeed; Rehan Zafar Paracha; Zumara Younas; Muhammad Tahir Khadim
Journal:  Int J Nanomedicine       Date:  2021-06-01

4.  Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection.

Authors:  Abolfazl Jahangiri; Parviz Owlia; Iraj Rasooli; Jafar Salimian; Ehsan Derakhshanifar; Zahra Aghajani; Sajad Abdollahi; Saeed Khalili; Daryush Talei; Elham Darzi Eslam
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

Review 5.  Promising Acinetobacter baumannii Vaccine Candidates and Drug Targets in Recent Years.

Authors:  Yong Chiang Tan; Chandrajit Lahiri
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

6.  A Systematic Study of the Stability, Safety, and Efficacy of the de novo Designed Antimicrobial Peptide PepD2 and Its Modified Derivatives Against Acinetobacter baumannii.

Authors:  Sung-Pang Chen; Eric H-L Chen; Sheng-Yung Yang; Pin-Shin Kuo; Hau-Ming Jan; Tsai-Chen Yang; Ming-Yen Hsieh; Kung-Ta Lee; Chun-Hung Lin; Rita P-Y Chen
Journal:  Front Microbiol       Date:  2021-06-18       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.